Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Tolerability and safety profile of pramipexole in the treatment of Parkinson's disease
Autore:
Armer, JA; Martin, WRW; Pogarell, O;
Indirizzi:
Med Ctr, Warrington WA5 5LZ, Cheshire, England Med Ctr Warrington Cheshire England WA5 5LZ on WA5 5LZ, Cheshire, England Glenrose Rehabil Hosp, Movement Disorder Clin, Edmonton, AB T5G 0B7, Canada Glenrose Rehabil Hosp Edmonton AB Canada T5G 0B7 nton, AB T5G 0B7, Canada Univ Munich, Dept Psychiat, Clin Neurophysiol Sect, D-80336 Munich, Germany Univ Munich Munich Germany D-80336 physiol Sect, D-80336 Munich, Germany
Titolo Testata:
REVIEWS IN CONTEMPORARY PHARMACOTHERAPY
fascicolo: 1-2, volume: 12, anno: 2001,
pagine: 105 - 124
SICI:
0954-8602(2001)12:1-2<105:TASPOP>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOPAMINE-RECEPTOR AGONIST; MOTOR-VEHICLE MISHAPS; SIDE-EFFECT PROFILE; DOUBLE-BLIND; FALLING ASLEEP; PLACEBO; BROMOCRIPTINE; ROPINIROLE; EFFICACY; SLEEP;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
60
Recensione:
Indirizzi per estratti:
Indirizzo: Armer, JA Box 15, Carnforth LA6 1HW, England Box 15 Carnforth England LA6 1HW 5, Carnforth LA6 1HW, England
Citazione:
J.A. Armer et al., "Tolerability and safety profile of pramipexole in the treatment of Parkinson's disease", REV CONT PH, 12(1-2), 2001, pp. 105-124

Abstract

Information regarding the tolerability and safety of pramipexole is derived primarily from clinical trials designed to examine the efficacy of this agent in the treatment of Parkinson's disease. In this review, the adverse event frequencies for pramipexole have been compared with those for placebo,where such information has been provided in accounts of placebo-controlled, double-blind trials. Analyses have been conducted on combined data from three studies involving patients with early Parkinson's disease and from five studies involving patients with advanced Parkinson's disease; an analysiswas also carried out on combined data from all eight trials. Although pramipexole has been investigated in depression, schizophrenia, restless legs syndrome, and in a variety of other conditions, medication-related adverse events noted in such studies have not been considered in the present analysis. The adverse event profiles for pramipexole, as used in early or advancedParkinson's disease, have been based on only those events for which the frequency with pramipexole was (a) at least 2.5%, (b) at least 5% greater than that with placebo, and (c) different from that with placebo to a statistically significant degree. For all eight studies combined, the resultant profile comprised only three symptoms: nausea, somnolence and hallucinations. For patients with early Parkinson's disease, the profile consisted of somnolence, nausea, hallucinations, constipation and dizziness; for patients with advanced Parkinson's disease, the profile consisted of dyskinesias, nausea, hallucinations, confusion and insomnia. It is suggested that the dyskinetic adverse events seen with pramipexole in patients with advanced Parkinson's disease may in part reflect the concomitant administration of L-DOPA attoo high a dose. In this review, other classes of reported adverse event have been noted, though in all cases their frequencies of occurrence were similar to, or sometimes less than, those seen with placebo treatment, and, except for a few of these events, there is little or no clear evidence of their causal relationship with pramipexole. in general, those adverse events which do appear to be associated with pramipexole treatment are mild-to-moderate in intensity, though adverse events may occasionally lead patients towithdraw from pramipexole treatment, or necessitate a reduction in the dose of pramipexole. It is concluded that pramipexole is a well tolerated treatment in both early and advanced Parkinson's disease.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/06/20 alle ore 01:22:36